Use of Amiodarone with Apixaban or Rivaroxaban Increases Risk for Bleeding-related Hospitalizations

This study was observational, and the Medicare data lacked information on several potential confounding factors, thereby limiting the ability to establish a causal relationship. However, hospitalists who are initiating antiarrhythmic drugs for atrial fibrillation should consider the potential increased risk for bleeding-related hospitalization in patients concurrently taking apixaban or rivaroxaban. Bottom line: Amiodarone, when used in conjunction with apixaban or rivaroxaban, increases the risk of bleeding-related hospitalization when compared to the use of flecainide or sotalol. Citation: Ray WA, et al. Risk for bleeding-related hospitalizations during use of amiodarone with apixaban or rivaroxaban in patients with atrial fibrillation: a retrospective cohort study. Ann Intern Med. 2023;176(6):769-78. Dr. Fang Dr. Schumacher Dr. Fang is a clinical assistant professor and Dr. Schumacher is a clinical associate professor in the division of hospital medicine at The Ohio State University Wexner Medical Center in Columbus, Ohio. The post Use of Amiodarone with Apixaban or Rivaroxaban Increases Risk for Bleeding-related Hospitalizations appeared first on The Hospitalist.
Source: The Hospitalist - Category: Hospital Management Authors: Tags: Hematology (blood) In the Literature Source Type: research